BRCA1/2 mutation carriers are potentially at higher cardiovascular risk

Critical Reviews in Oncology/Hematology

Volumn 91, Issue 2, 2014, Pages 159-171

  Arts de Jong, M ^a   Maas, A H E M ^a   Massuger, L F ^a   Hoogerbrugge, N ^a   de Hullu, J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BRCA mutation; Cardio oncology; Cardiovascular disease; Menopause; Risk reducing salpingo oophorectomy

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLIMACTERIUM; CONGESTIVE HEART FAILURE; DYSLIPIDEMIA; FEMALE INFERTILITY; GENE MUTATION; HEART LEFT VENTRICLE FAILURE; HER2 POSITIVE BREAST CANCER; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYSTERECTOMY; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MENOPAUSE; OBESITY; OVARIECTOMY; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; REVIEW; SALPINGOOOPHORECTOMY; SEDENTARY LIFESTYLE; SMOKING; THROMBOEMBOLISM; TUMOR SUPPRESSOR GENE; AGE; ANIMAL; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COMPLICATION; FEMALE; GENETIC PREDISPOSITION; GENETICS; MUTATION; OVARIAN NEOPLASMS; RISK FACTOR;

AGE FACTORS; ANIMALS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MENOPAUSE; MUTATION; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 84903488870     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.01.008     Document Type: Review

References (173)

1. Roett M.A., Evans P. Ovarian cancer: an overview. American Family Physician 2009, 80:609-616.
2. Heintz A.P., Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. International Journal of Gynaecology and Obstetrics 2006, 95(Suppl. 1):S161-S192.
3. Schorge J.O., Modesitt S.C., Coleman R.L., et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecologic and Oncology 2010, 119:7-17.
4. Alsop K., Fereday S., Meldrum C., et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology 2012, 30:2654-2663.
5. Zhang S., Royer R., Li S., et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecologic and Oncology 2011, 121:353-357.
6. Risch H.A., McLaughlin J.R., Cole D.E., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics 2001, 68:700-710.
7. Russo A., Calo V., Bruno L., Rizzo S., Bazan V., Di Fede G. Hereditary ovarian cancer. Critical Reviews in Oncology/Hematology 2009, 69:28-44.
8. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology 2007, 25:1329-1333.
9. Hermsen B.B., Olivier R.I., Verheijen R.H., et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers: an observational follow-up study. British Journal of Cancer 2007, 96:1335-1342.
10. Evans D.G., Gaarenstroom K.N., Stirling D., et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. Journal of Medical Genetics 2009, 46:593-597.
11. Rebbeck T.R., Kauff N.D., Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute 2009, 101:80-87.
12. Kauff N.D., Domchek S.M., Friebel T.M., et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. Journal of Clinical Oncology 2008, 26:1331-1337.
13. Ossewaarde M.E., Bots M.L., Verbeek A.L., et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005, 16:556-562.
14. Global status report on noncommunicable disease 2010 2011, World Health Organization, Geneva.
15. Mosca L., Barrett-Connor E., Wenger N.K. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 2011, 124:2145-2154.
16. Conroy R.M., Pyorala K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal 2003, 24:987-1003.
17. D'Agostino R.B., Vasan R.S., Pencina M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
18. Berry J.D., Liu K., Folsom A.R., et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation 2009, 119:382-389.
19. Berry J.D., Dyer A., Cai X., et al. Lifetime risks of cardiovascular disease. New England Journal of Medicine 2012, 366:321-329.
20. Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113:791-798.
21. Mosca L., Benjamin E.J., Berra K., et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update: a guideline from the American Heart Association. Circulation 2011, 123:1243-1262.
22. Mosca L., Hammond G., Mochari-Greenberger H., et al. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey. Circulation 2013, 127:1254-1263. e1-29.
23. Perk J., De Backer G., Gohlke H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European Heart Journal 2012, 33:1635-1701.
24. Hall J.M., Lee M.K., Newman B., et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250:1684-1689.
25. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
26. Easton D.F., Bishop D.T., Ford D., Crockford G.P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. American Journal of Human Genetics 1993, 52:678-701.
27. Burger H.G., Dudley E.C., Hopper J.L., et al. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. Journal of Clinical Endocrinology and Metabolism 1995, 80:3537-3545.
28. Thomford P.J., Jelovsek F.R., Mattison D.R. Effect of oocyte number and rate of atresia on the age of menopause. Reproductive Toxicology 1987, 1:41-51.
29. Woods N.F., Mitchell E.S. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. American Journal of Medicine 2005, 118(Suppl. 12B):14-24.
30. Gold E.B., Bromberger J., Crawford S., et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. American Journal of Epidemiology 2001, 153:865-874.
31. Morabia A., Costanza M.C. International variability in ages at menarche, first livebirth, and menopause. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. American Journal of Epidemiology 1998, 148:1195-1205.
32. Nelson L.M. Clinical practice. Primary ovarian insufficiency. New England Journal of Medicine 2009, 360:606-614.
33. Gold E.B., Crawford S.L., Avis N.E., et al. Factors related to age at natural menopause: longitudinal analyses from SWAN. American Journal of Epidemiology 2013, 178:70-83.
34. van der Schouw Y.T., van der Graaf Y., Steyerberg E.W., Eijkemans J.C., Banga J.D. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996, 347:714-718.
35. Atsma F., Bartelink M.L., Grobbee D.E., van der Schouw Y.T. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause (New York, NY) 2006, 13:265-279.
36. Jacobsen B.K., Knutsen S.F., Fraser G.E. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. Journal of Clinical Epidemiology 1999, 52:303-307.
37. Monninkhof E.M., van der Schouw Y.T., Peeters P.H. Early age at menopause and breast cancer: are leaner women more protected. A prospective analysis of the Dutch DOM cohort. Breast Cancer Research and Treatment 1999, 55:285-291.
38. Collaborative Group on Hormonal Factors in Breast Cancer Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118964 women with breast cancer from 117 epidemiological studies. Lancet Oncology 2012, 13:1141-1151.
39. Karageorgi S., Hankinson S.E., Kraft P., De Vivo I. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. International Journal of Cancer 2010, 126:208-216.
40. Joakimsen O., Bonaa K.H., Stensland-Bugge E., Jacobsen B.K. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis: the Tromso Study. Journal of Clinical Epidemiology 2000, 53:525-530.
41. Gulhan I., Bozkaya G., Uyar I., Oztekin D., Pamuk B.O., Dogan E. Serum lipid levels in women with premature ovarian failure. Menopause (New York, NY) 2012, 19:1231-1234.
42. Knauff E.A., Westerveld H.E., Goverde A.J., et al. Lipid profile of women with premature ovarian failure. Menopause (New York, NY) 2008, 15:919-923.
43. Kok H.S., van Asselt K.M., van der Schouw Y.T., et al. Heart disease risk determines menopausal age rather than the reverse. Journal of the American College of Cardiology 2006, 47:1976-1983.
44. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. New England Journal of Medicine 1999, 340:1801-1811.
45. Villablanca A.C., Jayachandran M., Banka C. Atherosclerosis and sex hormones: current concepts. Clinical Science 2010, 119:493-513.
46. Bittner V. Menopause, age, and cardiovascular risk: a complex relationship. Journal of the American College of Cardiology 2009, 54:2374-2375.
47. Do K.A., Green A., Guthrie J.R., Dudley E.C., Burger H.G., Dennerstein L. Longitudinal study of risk factors for coronary heart disease across the menopausal transition. American Journal of Epidemiology 2000, 151:584-593.
48. Berg G., Mesch V., Boero L., et al. Lipid and lipoprotein profile in menopausal transition. Effects of hormones, age and fat distribution. Hormone and Metabolic Research 2004, 36:215-220.
49. Matthews K.A., Crawford S.L., Chae C.U., et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition. Journal of the American College of Cardiology 2009, 54:2366-2373.
50. Derby C.A., Crawford S.L., Pasternak R.C., Sowers M., Sternfeld B., Matthews K.A. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. American Journal of Epidemiology 2009, 169:1352-1361.
51. Franklin R.M., Ploutz-Snyder L., Kanaley J.A. Longitudinal changes in abdominal fat distribution with menopause. Metabolism: Clinical and Experimental 2009, 58:311-315.
52. Abdulnour J., Doucet E., Brochu M., et al. The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa New Emerging Team group study. Menopause (New York, NY) 2012, 19:760-767.
53. Lovejoy J.C., Champagne C.M., de Jonge L., Xie H., Smith S.R. Increased visceral fat and decreased energy expenditure during the menopausal transition. International Journal of Obesity 2008, 32:949-958.
54. Lee C.G., Carr M.C., Murdoch S.J., et al. Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. Journal of Clinical Endocrinology and Metabolism 2009, 94:1104-1110.
55. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
56. Yusuf S., Hawken S., Ounpuu S., et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005, 366:1640-1649.
57. Moreau K.L., Hildreth K.L., Meditz A.L., Deane K.D., Kohrt W.M. Endothelial function is impaired across the stages of the menopause transition in healthy women. Journal of Clinical Endocrinology and Metabolism 2012, 97:4692-4700.
58. El Khoudary S.R., Wildman R.P., Matthews K., Thurston R.C., Bromberger J.T., Sutton-Tyrrell K. Progression rates of carotid intima-media thickness and adventitial diameter during the menopausal transition. Menopause (New York, NY) 2013, 20:8-14.
59. Wildman R.P., Schott L.L., Brockwell S., Kuller L.H., Sutton-Tyrrell K. A dietary and exercise intervention slows menopause-associated progression of subclinical atherosclerosis as measured by intima-media thickness of the carotid arteries. Journal of the American College of Cardiology 2004, 44:579-585.
60. Johnson B.D., Dwyer K.M., Stanczyk F.Z., et al. The relationship of menopausal status and rapid menopausal transition with carotid intima-media thickness progression in women: a report from the Los Angeles Atherosclerosis Study. Journal of Clinical Endocrinology and Metabolism 2010, 95:4432-4440.
61. Munir J.A., Wu H., Bauer K., et al. The perimenopausal atherosclerosis transition: relationships between calcified and noncalcified coronary, aortic, and carotid atherosclerosis and risk factors and hormone levels. Menopause (New York, NY) 2012, 19:10-15.
62. Gast G.C., Grobbee D.E., Pop V.J., et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension 2008, 51:1492-1498.
63. Gast G.C., Samsioe G.N., Grobbee D.E., Nilsson P.M., van der Schouw Y.T. Vasomotor symptoms, estradiol levels and cardiovascular risk profile in women. Maturitas 2010, 66:285-290.
64. Thurston R.C., El Khoudary S.R., Sutton-Tyrrell K., et al. Vasomotor symptoms and lipid profiles in women transitioning through menopause. Obstetrics and Gynecology 2012, 119:753-761.
65. Thurston R.C., El Khoudary S.R., Sutton-Tyrrell K., et al. Vasomotor symptoms and insulin resistance in the study of women's health across the nation. Journal of Clinical Endocrinology and Metabolism 2012, 97:3487-3494.
66. Thurston R.C., Sutton-Tyrrell K., Everson-Rose S.A., Hess R., Matthews K.A. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. Circulation 2008, 118:1234-1240.
67. Thurston R.C., Sutton-Tyrrell K., Everson-Rose S.A., Hess R., Powell L.H., Matthews K.A. Hot flashes and carotid intima media thickness among midlife women. Menopause (New York, NY) 2011, 18:352-358.
68. Lambrinoudaki I., Augoulea A., Armeni E., et al. Menopausal symptoms are associated with subclinical atherosclerosis in healthy recently postmenopausal women. Climacteric 2012, 15:350-357.
69. Allison M.A., Manson J.E., Aragaki A., et al. Vasomotor symptoms and coronary artery calcium in postmenopausal women. Menopause (New York, NY) 2010, 17:1136-1145.
70. Wolff E.F., He Y., Black D.M., et al. Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos early estrogen prevention study (KEEPS). Fertility and Sterility 2013, 99:1385-1391.
71. Szmuilowicz E.D., Manson J.E., Rossouw J.E., et al. Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause (New York, NY) 2011, 18:603-610.
72. Gibson C.J., Thurston R.C., El Khoudary S.R., Sutton-Tyrrell K., Matthews K.A. Body mass index following natural menopause and hysterectomy with and without bilateral oophorectomy. International Journal of Obesity 2013, 37:809-813.
73. Tuna V., Alkis I., Safiye A.S., Imamoglu N., Bayram N., Ali Ismet T. Variations in blood lipid profile, thrombotic system, arterial elasticity and psychosexual parameters in the cases of surgical and natural menopause. Australian & New Zealand Journal of Obstetrics & Gynaecology 2010, 50:194-199.
74. Ozkaya E., Cakir E., Okuyan E., Cakir C., Ustun G., Kucukozkan T. Comparison of the effects of surgical and natural menopause on carotid intima media thickness, osteoporosis, and homocysteine levels. Menopause (New York, NY) 2011, 18:73-76.
75. Mack W.J., Slater C.C., Xiang M., Shoupe D., Lobo R.A., Hodis H.N. Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertility and Sterility 2004, 82:391-397.
76. Mihmanli V., Mihmanli I., Atakir K., et al. Carotid intima-media thickness in surgical menopause: women who received HRT versus who did not. Maturitas 2002, 42:37-43.
77. Mihmanli V., Mihmanli I., Kantarci F., Aydin T., Yilmaz M.H., Ogut G. Carotid pulsatility indices in surgical menopause. Archives of Gynecology and Obstetrics 2002, 266:96-100.
78. Dwyer K.M., Nordstrom C.K., Bairey Merz C.N., Dwyer J.H. Carotid wall thickness and years since bilateral oophorectomy: the Los Angeles Atherosclerosis Study. American Journal of Epidemiology 2002, 156:438-444.
79. Ingelsson E., Lundholm C., Johansson A.L., Altman D. Hysterectomy and risk of cardiovascular disease: a population-based cohort study. European Heart Journal 2011, 32:745-750.
80. Parker W.H., Broder M.S., Chang E., et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstetrics and Gynecology 2009, 113:1027-1037.
81. Matthews K.A., Gibson C.J., El Khoudary S.R., Thurston R.C. Changes in cardiovascular risk factors by hysterectomy status with and without oophorectomy: Study of Women's Health Across the Nation. Journal of the American College of Cardiology 2013, 62:191-200.
82. Jacoby V.L., Grady D., Wactawski-Wende J., et al. Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Archives of Internal Medicine 2011, 171:760-768.
83. Howard B.V., Kuller L., Langer R., et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation 2005, 111:1462-1470.
84. Rocca W.A., Grossardt B.R., de Andrade M., Malkasian G.D., Melton L.J. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncology 2006, 7:821-828.
85. Rivera C.M., Grossardt B.R., Rhodes D.J., et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause (New York, NY) 2009, 16:15-23.
86. Parker W.H., Feskanich D., Broder M.S., et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstetrics and Gynecology 2013, 121:709-716.
87. Siddle N., Sarrel P., Whitehead M. The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertility and Sterility 1987, 47:94-100.
88. Moorman P.G., Myers E.R., Schildkraut J.M., Iversen E.S., Wang F., Warren N. Effect of hysterectomy with ovarian preservation on ovarian function. Obstetrics and Gynecology 2011, 118:1271-1279.
89. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine 1991, 20:47-63.
90. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of American Medical Association 2002, 288:321-333.
91. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Journal of American Medical Association 1998, 280:605-613.
92. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. New England Journal of Medicine 2000, 343:522-529.
93. Hodis H.N., Mack W.J., Azen S.P., et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. New England Journal of Medicine 2003, 349:535-545.
94. Wharton W., Gleason C.E., Miller V.M., Asthana S. Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog). Brain Research 2013, 1514:12-17.
95. Marjoribanks J., Farquhar C., Roberts H., Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. The Cochrane Database of Systematic Reviews 2012, 7:CD004143.
96. Clarkson T.B., Melendez G.C., Appt S.E. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause (New York, NY) 2013, 20:342-353.
97. Manson J.E., Allison M.A., Rossouw J.E., et al. Estrogen therapy and coronary-artery calcification. New England Journal of Medicine 2007, 356:2591-2602.
98. Rossouw J.E., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. Journal of American Medical Association 2007, 297:1465-1477.
99. Sophonsritsuk A., Appt S.E., Clarkson T.B., Shively C.A., Espeland M.A., Register T.C. Differential effects of estradiol on carotid artery inflammation when administered early versus late after surgical menopause. Menopause (New York, NY) 2013, 20:540-547.
100. Schierbeck L.L., Rejnmark L., Tofteng C.L., et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. British Medical Journal (Clinical Research Ed.) 2012, 345:e6409.
101. Salpeter S.R., Buckley N.S., Liu H., Salpeter E.E. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. American Journal of Medicine 2009, 122:42-52. e2.
102. North American Menopause Society The 2012 hormone therapy position statement of the North American Menopause Society. Menopause (New York, NY) 2012, 19:257-271.
103. Panay N., Hamoda H., Arya R., Savvas M., British Menopause Society, Women's Health Concern The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy. Menopause International 2013, 19:59-68.
104. Bellamy L., Casas J.P., Hingorani A.D., Williams D.J. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. British Medical Journal (Clinical Research Ed.) 2007, 335:974.
105. McDonald S.D., Malinowski A., Zhou Q., Yusuf S., Devereaux P.J. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. American Heart Journal 2008, 156:918-930.
106. Brown M.C., Best K.E., Pearce M.S., Waugh J., Robson S.C., Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. European Journal of Epidemiology 2013, 28:1-19.
107. Manten G.T., Sikkema M.J., Voorbij H.A., Visser G.H., Bruinse H.W., Franx A. Risk factors for cardiovascular disease in women with a history of pregnancy complicated by preeclampsia or intrauterine growth restriction. Hypertension in Pregnancy: Official Journal of the International Society for the Study of Hypertension in Pregnancy 2007, 26:39-50.
108. Blaauw J., van Pampus M.G., Van Doormaal J.J., et al. Increased intima-media thickness after early-onset preeclampsia. Obstetrics and Gynecology 2006, 107:1345-1351.
109. McDonald S.D., Ray J., Teo K., et al. Measures of cardiovascular risk and subclinical atherosclerosis in a cohort of women with a remote history of preeclampsia. Atherosclerosis 2013, 229:234-239.
110. Sabour S., Franx A., Rutten A., et al. High blood pressure in pregnancy and coronary calcification. Hypertension 2007, 49:813-817.
111. Drost J., van der Schouw Y., Maas A., Verschuren W. Longitudinal analysis of cardiovascular risk parameters in women with a history of hypertensive pregnancy disorders: the Doetinchem Cohort Study. BJOG 2013, 120:1333-1339.
112. Drost J.T., van der Schouw Y.T., Herber-Gast G.C., Maas A.H. More vasomotor symptoms in menopause among women with a history of hypertensive pregnancy diseases compared with women with normotensive pregnancies. Menopause (New York, NY) 2013, 20:1006-1011.
113. Pirkola J., Pouta A., Bloigu A., et al. Prepregnancy overweight and gestational diabetes as determinants of subsequent diabetes and hypertension after 20-year follow-up. Journal of Clinical Endocrinology and Metabolism 2010, 95:772-778.
114. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics 2003, 72:1117-1130.
115. Mavaddat N., Peock S., Frost D., et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of the National Cancer Institute 2013, 105:812-822.
116. Brohet R.M., Velthuizen M.E., Hogervorst F.B., et al. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. Journal of Medical Genetics 2014, 51:98-107.
117. Metcalfe K.A., Birenbaum-Carmeli D., Lubinski J., et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Jouanl of Cancer 2008, 122:2017-2022.
118. Skytte A.B., Gerdes A.M., Andersen M.K., et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clinical Genetics 2010, 77:342-349.
119. Meijers-Heijboer E.J., Verhoog L.C., Brekelmans C.T., et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000, 355:2015-2020.
120. Evans D.G., Lalloo F., Ashcroft L., et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009, 18:2318-2324.
121. Schwartz M.D., Isaacs C., Graves K.D., et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer 2012, 118:510-517.
122. Beattie M.S., Crawford B., Lin F., Vittinghoff E., Ziegler J. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genetic Testing and Molecular Biomarkers 2009, 13:51-56.
123. Singh K., Lester J., Karlan B., Bresee C., Geva T., Gordon O. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. American Journal of Obstetrics and Gynecology 2013, 208:329 e1-3296e.
124. van Driel C.M., Eltahir Y., de Vries J., et al. Risk-reducing mastectomy in BRCA1/2 mutation carriers: factors influencing uptake and timing. Maturitas 2014, 77:180-184.
125. Lenihan D.J., Cardinale D.M. Late cardiac effects of cancer treatment. Journal of Clinical Oncology 2012, 30:3657-3664.
126. Lenihan D.J., Cardinale D., Cipolla C.M. The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Progress in Cardiovascular Diseases 2010, 53:88-93.
127. Khouri M.G., Douglas P.S., Mackey J.R., et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation 2012, 126:2749-2763.
128. Jones L.W., Haykowsky M.J., Swartz J.J., Douglas P.S., Mackey J.R. Early breast cancer therapy and cardiovascular injury. Journal of the American College of Cardiology 2007, 50:1435-1441.
129. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine 1979, 91:710-717.
130. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
131. Cardinale D., Colombo A., Lamantia G., et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology 2010, 55:213-220.
132. Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. New England Journal of Medicine 2011, 365:1273-1283.
133. Hooning M.J., Botma A., Aleman B.M., et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. Journal of the National Cancer Institute 2007, 99:365-375.
134. Early Breast Cancer Trialists' Collaborative Group, Darby S., McGale P., et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011, 378:1707-1716.
135. Whelan T.J., Julian J., Wright J., Jadad A.R., Levine M.L. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. Journal of Clinical Oncology 2000, 18:1220-1229.
136. Taylor C.W., Povall J.M., McGale P., et al. Cardiac dose from tangential breast cancer radiotherapy in the year 2006. International Journal of Radiation Oncology, Biology, Physics 2008, 72:501-507.
137. Witteles R.M. Radiation therapy for breast cancer: buyer beware. Journal of the American College of Cardiology 2011, 57:453-454.
138. Darby S.C., Ewertz M., McGale P., et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. New England Journal of Medicine 2013, 368:987-998.
139. Bouillon K., Haddy N., Delaloge S., et al. Long-term cardiovascular mortality after radiotherapy for breast cancer. Journal of the American College of Cardiology 2011, 57:445-452.
140. Bradbury B.D., Lash T.L., Kaye J.A., Jick S.S. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer 2005, 103:1114-1121.
141. Braithwaite R.S., Chlebowski R.T., Lau J., George S., Hess R., Col N.F. Meta-analysis of vascular and neoplastic events associated with tamoxifen. Journal of General Internal Medicine 2003, 18:937-947.
142. Stamatelopoulos K.S., Lekakis J.P., Poulakaki N.A., et al. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. American Heart Journal 2004, 147:1093-1099.
143. Amir E., Seruga B., Niraula S., Carlsson L., Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. Journal of the National Cancer Institute 2011, 103:1299-1309.
144. Cuppone F., Bria E., Verma S., et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 2008, 112:260-267.
145. Welcsh P.L., King M.C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Human Molecular Genetics 2001, 10:705-713.
146. Botto N., Rizza A., Colombo M.G., et al. Evidence for DNA damage in patients with coronary artery disease. Mutation Research 2001, 493:23-30.
147. Oh H., Wang S.C., Prahash A., et al. Telomere attrition and Chk2 activation in human heart failure. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:5378-5383.
148. Olivetti G., Abbi R., Quaini F., et al. Apoptosis in the failing human heart. New England Journal of Medicine 1997, 336:1131-1141.
149. Mai P.L., Chatterjee N., Hartge P., et al. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma. PLoS ONE 2009, 4:e4812.
150. Bordeleau L., Lipscombe L., Lubinski J., et al. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 2011, 117:1812-1818.
151. Asselbergs F.W., Guo Y., van Iperen E.P., et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. American Journal of Human Genetics 2012, 91:823-838.
152. Shukla P.C., Singh K.K., Quan A., et al. BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nature Communications 2011, 2:593.
153. Singh K.K., Shukla P.C., Yanagawa B., et al. Regulating cardiac energy metabolism and bioenergetics by targeting the DNA damage repair protein BRCA1. Journal of Thoracic and Cardiovascular Surgery 2013, 146:702-709.
154. Singh K.K., Shukla P.C., Quan A., et al. BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis. Journal of Thoracic and Cardiovascular Surgery 2013, 146:949-960 e4.
155. Singh K.K., Shukla P.C., Quan A., et al. BRCA2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure. Journal of Biological Chemistry 2012, 287:6604-6614.
156. Konishi H., Mohseni M., Tamaki A., et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:17773-17778.
157. Snieder H., MacGregor A.J., Spector T.D. Genes control the cessation of a woman's reproductive life: a twin study of hysterectomy and age at menopause. Journal of Clinical Endocrinology and Metabolism 1998, 83:1875-1880.
158. Oktay K., Kim J.Y., Barad D., Babayev S.N. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. Journal of Clinical Oncology 2010, 28:240-244.
159. Finch A., Valentini A., Greenblatt E., et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertility and Sterility 2013, 99:1724-1728.
160. Lin W.T., Beattie M., Chen L.M., et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer 2013, 119:1652-1659.
161. Tea M.K., Weghofer A., Wagner K., Singer C.F. Association of BRCA1/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age. Maturitas 2013, 75:148-151.
162. Brandao R.D., van Roozendaal K., Tserpelis D., Blok M.J. FMR1 low sub-genotype does not rescue BRCA1/2-mutated human embryos and does not explain primary ovarian insufficiency among BRCA1/2-carriers. Human Reproduction 2013, 28:2308-2311.
163. Titus S., Li F., Stobezki R., et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Science Translational Medicine 2013, 5:172ra21.
164. Moslehi R., Singh R., Lessner L., Friedman J.M. Impact of BRCA mutations on female fertility and offspring sex ratio. American Journal of Human Biology: The Official Journal of the Human Biology Council 2010, 22:201-205.
165. Michelsen T.M., Tonstad S., Pripp A.H., Trope C.G., Dorum A. Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. International Journal of Gynecological Cancer 2010, 20:233-239.
166. Michelsen T.M., Pripp A.H., Tonstad S., Trope C.G., Dorum A. Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. European Journal of Cancer 2009, 45:82-89.
167. Cohen J.V., Chiel L., Boghossian L., et al. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Familial Cancer 2012, 11:69-75.
168. Rebbeck T.R., Friebel T., Wagner T., et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. Journal of Clinical Oncology 2005, 23:7804-7810.
169. Challberg J., Ashcroft L., Lalloo F., et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. British Journal of Cancer 2011, 105:22-27.
170. Madalinska J.B., van Beurden M., Bleiker E.M., et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. Journal of Clinical Oncology 2006, 24:3576-3582.
171. Finch A., Metcalfe K.A., Chiang J.K., et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecologic and Oncology 2011, 121:163-168.
172. Armstrong K., Schwartz J.S., Randall T., Rubin S.C., Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. Journal of Clinical Oncology 2004, 22:1045-1054.
173. Finch A., Evans G., Narod S.A. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Women's Health (London, England) 2012, 8:543-555.